Back

Heterogeneous effectiveness of SGLT2 inhibitors for individuals without established CVDs: A population based study with machine learning approach

31 August 2025 (15:00 - 15:10)
Organised by: Logo
Congress Presentation Part of: Broadening phenotype of diabetic heart disease Diabetes and the Heart ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Takahiro Jimba

The University of Tokyo, Tokyo (Japan)

3 More presentations in this session

Presentation thumbnail
Diabetes and prediabetes as risk factors for heart failure: a population-based cohort study of 110 000 individuals
Doctor M. Reinert (Lycksele, SE)
Abstract Slides Video
Presentation thumbnail
Associations between prediabetes and diabetes mellitus type 2 and incident atrial fibrillation in patients with hypertension; results from the Swedish Primary Care Cardiovascular Database
Doctor S. Bentzel (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
The effect of metabolic syndrome on the relation between lipoprotein (a) and incident type 2 diabetes and outcome: observations from the UK-Biobank.
Doctor J. Sangha (Cambridge, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Broadening phenotype of diabetic heart disease
Video

The Event

Event poster

ESC Congress 2025

31 August 2025 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Heterogeneous effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular events among people with type 2 diabetes: an application of machine learning to target trial emulation
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Presentation
Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources